Triple therapy of initial high-dose interferon with ribavirin and amantadine for patients with chronic hepatitis C

Hepatology Research

Volumn 37, Issue 5, 2007, Pages 325-330

  Uyama, Hirokazu ^a   Nakamura, Hideji ^b   Hayashi, Eijiro ^c   Ogawa, Hiroyuki ^d   Enomoto, Hirayuki ^d   Yoshida, Kenya ^a   Okuda, Yorihide ^a   Yamamoto, Mitsunari ^e   Hada, Toshikazu ^b   Hayashi, Norio ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b HYOGO COLLEGE OF MEDICINE   (Japan)

^c Kinki Central Hospital of Mutual Association of Public School Teachers   (Japan)

^d Nishinomiya Municipal Central Hospital   (Japan)

^e Tondabayashi Hospital   (Japan)

Author keywords

Amantadine; Chronic hepatitis C; Interferon; Ribavirin

Indexed keywords

ALPHA2B INTERFERON; AMANTADINE; BETA INTERFERON; RIBAVIRIN; VIRUS RNA;

ADULT; AGED; ANEMIA; ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DEPRESSION; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG RESPONSE; DRUG WITHDRAWAL; ECZEMA; ERADICATION THERAPY; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; MALE; PILOT STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; VIRUS LOAD;

EID: 34247182106     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2007.00044.x     Document Type: Article

References (43)

1. Hu KQ, Vierling JM, Redeker AG. Viral, host and interferon-related factors modulating the effect of interferon therapy for hepatitis C virus infection. J Viral Hepat 2001; 8: 1-18.
2. Conjeevaram HS, Everhart JE, Hoofnagle JH. Prediction of a sustained beneficial response to interferon alpha therapy in chronic hepatitis C. Hepatology 1995; 22: 1326-9.
3. Davis GL, Lau JYN. Factors predictive of a beneficial response to therapy of hepatitis C. Hepatology 1997; 26: 122S-7 S.
4. Shiratori Y, Kato N, Yokosuka O et al. Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection. Tokyo-Chiba Hepatitis Research Group. Gastroenterology 1997; 113: 558-66.
5. Nakamura H, Ito H, Ogawa H et al. Initial daily interferon administration can gain more eradication of HCV-RNA in patients with chronic hepatitis C, especially with serum intermediate viral load. Hepatogastroenterology 1999; 46: 1131-9.
6. Chayama K, Suzuki F, Tsubota A et al. Evaluation of quantitative measurements of hepatitis C virus RNA to predict sustained response to interferon by genotype. J Virol Methods 2001; 95: 33-45.
7. McHutchison JG, Poynard T. Combination therapy with interferon plus ribavirin for the initial treatment of chronic hepatitis C. Semin Liver Dis 1999; 19 (Suppl 1): 57-65.
8. Pol S, Naplas B, Bourliere M et al. Combination of ribavirin and interferon-alfasurpasses high doses of interferon-alfa alone in patients with genotype 1b related chronic hepatitis C. Hepatology 2000; 31: 1338-44.
9. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.
10. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 2002; 358: 958-65.
11. Tsubota A, Arase Y, Suzuki Y et al. Early viral kinetics and treatment outcome in combination of high dose interferon induction vs. pegylated interferon plus ribavirin for naïve patients infected with hepatitis C virus of genotype 1b and high viral load. J Med Virol 2005; 75: 27-34.
12. Skehel JJ, Hay AJ, Armstrong JA. On the mechanism of inhibition of influenza virus replication by amantadine hydrochloride. J Gen Virol 1978; 38: 97-110.
13. Koff WC, Elm JL Jr, Halstead SB. Inhibition of dengue virus replication by amantadine hydrochloride. Antimicrob Agents Chemother 1980; 18: 125-9.
14. Deltenre P, Henrion J, Canva V et al. Evaluation of amantadine in chronic hepatitis C: A meta-analysis. J Hepatol 2004; 41: 462-73.
15. Nakamura H. Efficacy of amantadine hydrochloride in patients with chronic hepatitis C. J Gastroenterol 2001; 36: 792-3.
16. Berg T, Kronenberger B, Hinrichsen H et al. Triple therapy with amantadine in treatment-naïve patients with chronic hepatitis C: A placebo-controlled trial. Hepatology 2003; 37: 1359-67.
17. Younossi ZM, Mullen KD, Hodnick S et al. Triple combination of interferon alpha-2b, ribavirin, and amantadine for treatment of chronic hepatitis C. J Clin Gastroenterol 2003; 36: 427-30.
18. Adinolfi LE, Utili R, Tonziello A et al. Effects of alpha interferon induction plus ribavirin with or without amantadine in the treatment of interferon non-responsive chronic hepatitis C: A randomised trial. Gut 2003; 52: 701-5.
19. Thuluvath PJ, Maheshwari A, Mehdi J et al. Randomised, double blind, placebo controlled trial of interferon, ribavirin, and amantadine versus interferon, ribavirin, and placebo in treatment naïve patients with chronic hepatitis C. Gut 2004; 53: 130-5.
20. Mangia A, Ricci GL, Persico M et al. A randomized controlled trial of pegylated interferon alpha-2a (40 KD) or interferon alpha-2a plus ribavirin and amantadine vs interferon alpha-2a and ribavirin in treatment-naive patients with chronic hepatitis C. J Viral Hepat 2005; 12: 292-9.
21. Younossi ZM, McCullough AC, Bames DS et al. Pegylated interferon alpha-2b, ribavirin and amantadine for chronic hepatitis C. Dig Dis Sci 2005; 50: 970-5.
22. Maynard M, Pradat P, Bailly F et al. Amantadine triple therapy for non-responder hepatitis C patients. Clues for controversies (ANRS HC 03 BITRI). J Hepatol 2006; 44: 484-90.
23. Ferenci P, Formann E, Laferl H et al. Randomised, double-blind, placebo-controlled study of peginterferon alpha-2a (40 KD) plus ribavirin with or without amantadine in treatment-naïve patients with chronic hepatitis C genotype 1 infection. J Hepatol 2006; 44: 275-82.
24. Aoki FY, Sitar DS. Clinical pharmacokinetics of amantadine hydrochloride. Clin Pharmacokinet 1988; 14: 35-51.
25. Smith JP. Treatment of chronic hepatitis C with amantadine. Dig Dis Sci 1997; 42: 1681-7.
26. Tabone M, Ercole E, Zaffino C et al. Amantadine hydrochloride decreases serum ALT activity without effects on serum HCV-RNA in chronic hepatitis C patients. Ital J Gastroenterol Hepatol 1998; 30: 611-13.
27. Younossi ZM, Perrillo RP. The roles of amantadine, rimantadine, ursodeoxycholic acid, and NSAIDs, alone or in combination with alpha interferons, in the treatment of chronic hepatitis C. Semin Liver Dis 1999; 19 (Suppl 1): 95-102.
28. Andant C, Lamoril J, Deybach JC et al. Amantadine for chronic hepatitis C: Pilot study in 14 patients. Eur J Gastroenterol Hepatol 2000; 12: 1319-22.
29. Goff JS, Reveille RM, Johnson J. Treatment of chronic hepatitis C with amantadine. Dig Dis Sci 2000; 45: 1389-91.
30. Senturk H, Mert A, Akdogan M et al. Amantadine monotherapy of chronic hepatitis C patients infected with genotype lb. Scand J Infect Dis 2000; 32: 575-6.
31. Yagura M, Harada H. Treatment of chronic hepatitis C patients with amantadine. J Gastroenterol 2001; 36: 759-63.
32. Iino S, Tomita E, Kumada H et al. Prediction of treatment outcome with daily high-dose IFN alpha-2b plus ribavirin in patients with chronic hepatitis C with genotype 1b and high HCV-RNA levels: Relationship of baseline viral levels and viral dynamics during and after therapy. Hepatol Res 2004; 30: 63-70.
33. Nakamura H, Ito H, Kimura Y et al. The importance of initial daily administration of interferon alpha for the eradication of hepatitis C virus in patients with chronic hepatitis C: A multicenter randomized trial. Hepatogastroenterology 1998; 45: 1045-55.
34. Okamoto H, Okada S, Sugiyama Y et al. The 5′-terminal sequence of the hepatitis C virus genome. Jpn J Exp Med 1990; 60: 167-77.
35. Hagiwara H, Hayashi N, Mita E et al. Quantitative analysis of hepatitis C virus RNA in serum during interferon alfa therapy. Gastroenterology 1993; 104: 877-83.
36. Hagiwara H, Hayashi N, Mita E et al. Detection of hepatitis C virus RNA in serum of patients with chronic hepatitis C treated with interferon-alpha. Hepatology 1992; 15: 37-41.
37. Okamoto H, Sugiyama Y, Okada S et al. Typing hepatitis C virus by polymerase chain reaction with type-specific primers: Application to clinical surveys and tracing infectious sources. J Gen Virol 1992; 73: 673-9.
38. Henkel JR, Weisz OA. Influenza virus M2 protein slows traffic along the secretory pathway: PH perturbation of acidified compartments affects early Golgi transport steps. J Biol Chem 1998; 273: 6518-24.
39. Kanda T, Yokosuka O, Imazeki F et al. Amantadine inhibits hepatitis A virus internal ribosomal entry site-mediated translation in human hepatoma cells. Biochem Biophys Res Commun 2005; 331: 621-9.
40. Griffin SD, Harvey R, Clarke DS et al. A. conserved basic loop in hepatitis C virus p7 protein is required for amantadine-sensitive ion channel activity in mammalian cells but is dispensable for localization to mitochondria. J Gen Virol 2004; 85: 451-61.
41. Uyama H, Enomoto H, Kishima Y et al. A. pilot study of combination therapy with initial high-dose interferon and amantadine hydrochloride for patients with chronic hepatitis C with the genotype 1b virus. Hepatogastroenterology 2003; 50: 2112-16.
42. Nakamura H, Uyama H, Enomoto H et al. The combination therapy of interferon and amantadine hydrochloride for patients with chronic hepatitis C. Hepatogastroenterology 2003; 50: 222-6.
43. Brillanti S, Miglioli M, Barbara L, Combination antiviral therapy with ribavirin and interferon alfa in interferon alfa relapsers and non-responders: Italian experience. J Hepatol 1995; 23 (Suppl 2): 13-5.